Diana Lüftner

5.4k total citations
176 papers, 2.4k citations indexed

About

Diana Lüftner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Diana Lüftner has authored 176 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 84 papers in Pulmonary and Respiratory Medicine and 52 papers in Cancer Research. Recurrent topics in Diana Lüftner's work include Advanced Breast Cancer Therapies (72 papers), HER2/EGFR in Cancer Research (63 papers) and Breast Cancer Treatment Studies (46 papers). Diana Lüftner is often cited by papers focused on Advanced Breast Cancer Therapies (72 papers), HER2/EGFR in Cancer Research (63 papers) and Breast Cancer Treatment Studies (46 papers). Diana Lüftner collaborates with scholars based in Germany, United States and Switzerland. Diana Lüftner's co-authors include K. Possinger, Kurt Possinger, C. Jehn, Bernd Flath, Marcus Reif, Florian Strasser, Gernot Ernst, Winfried Meißner, Martin Schnelle and Thomas Ruhstaller and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Diana Lüftner

160 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diana Lüftner Germany 27 1.4k 547 523 489 400 176 2.4k
Ana Barac United States 38 1.6k 1.2× 850 1.6× 658 1.3× 856 1.8× 331 0.8× 157 4.8k
Chun‐Chieh Lin Taiwan 13 1.1k 0.8× 765 1.4× 634 1.2× 177 0.4× 441 1.1× 39 2.9k
Camilo E. Fadul United States 34 1.4k 1.0× 569 1.0× 796 1.5× 350 0.7× 276 0.7× 113 3.9k
Masahiko Watanabe Japan 22 716 0.5× 450 0.8× 382 0.7× 328 0.7× 177 0.4× 78 1.9k
Robin Grant United Kingdom 32 1.9k 1.4× 461 0.8× 1.3k 2.5× 380 0.8× 264 0.7× 102 4.6k
Bhupendra Rawal United States 26 958 0.7× 705 1.3× 705 1.3× 266 0.5× 246 0.6× 76 2.9k
Summer S. Han United States 29 1.2k 0.8× 353 0.6× 1.5k 2.9× 452 0.9× 233 0.6× 125 3.3k
Andrew Stone United Kingdom 23 753 0.5× 1.1k 2.0× 407 0.8× 244 0.5× 542 1.4× 59 2.9k
Andrea Pace Italy 39 1.3k 0.9× 527 1.0× 1.2k 2.4× 399 0.8× 323 0.8× 170 4.7k

Countries citing papers authored by Diana Lüftner

Since Specialization
Citations

This map shows the geographic impact of Diana Lüftner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Lüftner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Lüftner more than expected).

Fields of papers citing papers by Diana Lüftner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Lüftner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Lüftner. The network helps show where Diana Lüftner may publish in the future.

Co-authorship network of co-authors of Diana Lüftner

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Lüftner. A scholar is included among the top collaborators of Diana Lüftner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Lüftner. Diana Lüftner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Untch, Michael, Nina Ditsch, Peter A. Fasching, et al.. (2024). Discussion of ABC7 Consensus and German Recommendations. Geburtshilfe und Frauenheilkunde. 84(5). 431–442. 1 indexed citations
2.
Lüftner, Diana. (2023). Zielgerichtete Therapie im Rezidiv 1. 29(5). 431–434.
3.
4.
5.
Pivot, Xavier, Javier Cortés, Diana Lüftner, et al.. (2023). Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer. JAMA Network Open. 6(4). e235822–e235822. 7 indexed citations
6.
Giesler, Marianne, et al.. (2023). Karriere in der Hämatologie und medizinischen Onkologie. 29(4). 358–365. 1 indexed citations
7.
Brucker, Cosima, Thomas Decker, PA Fasching, et al.. (2023). 441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study. Annals of Oncology. 34. S366–S367. 1 indexed citations
8.
Untch, Michael, Peter A. Fasching, Renate Haidinger, et al.. (2022). Advanced Breast Cancer. Geburtshilfe und Frauenheilkunde. 82(10). 1044–1054. 4 indexed citations
9.
Harbeck, Nadia, Andreas Schneeweiß, Peter Thuss‐Patience, et al.. (2021). Neoadjuvant and adjuvant end-points in health technology assessment in oncology. European Journal of Cancer. 147. 40–50. 9 indexed citations
10.
Gjerga, Enio, Steffen Hennig, Sigrid Schaper, et al.. (2021). Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial. European Journal of Cancer. 162. 45–55. 19 indexed citations
11.
Lüftner, Diana, Hans Tesch, Marcus Schmidt, et al.. (2021). Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment–driven analyses from the ExteNET study. European Journal of Cancer. 150. 268–277. 4 indexed citations
12.
Bokemeyer, Carsten, Michael Hallek, Diana Lüftner, & Florian Weißinger. (2019). Vorwort. Oncology Research and Treatment. 42(Suppl. 3). 1–1.
13.
Armbrust, Robert, Peter Thuss‐Patience, Diana Lüftner, et al.. (2019). Patients’ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life—a study of the North-Eastern-German Society of Gynecological Oncology. Archives of Gynecology and Obstetrics. 299(5). 1385–1389. 2 indexed citations
14.
Untch, Michael, Doris Augustin, Johannes Ettl, et al.. (2016). ABC3 Consensus Commented from the Perspective of the German Guidelines. Geburtshilfe und Frauenheilkunde. 76(2). 156–163. 7 indexed citations
15.
Fasching, Peter A., Sara Y. Brucker, Tanja Fehm, et al.. (2015). Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe und Frauenheilkunde. 75(1). 41–50. 43 indexed citations
16.
Hechmati, Guy, Amit Bahl, Diana Lüftner, et al.. (2011). PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY. Value in Health. 14(3). A168–A168. 3 indexed citations
17.
Esteva, Francisco J., Carol D Cheli, Herbert A. Fritsche, et al.. (2005). Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Research. 7(4). R436–43. 115 indexed citations
18.
Lüftner, Diana, et al.. (2004). Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.. PubMed. 24(2B). 895–906. 19 indexed citations
19.
Lüftner, Diana, et al.. (2004). Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma.. PubMed. 24(5B). 3233–7. 3 indexed citations
20.
Harris, Lyndsay N., Diana Lüftner, W. Jäger, & John F. R. Robertson. (1999). C-erbB-2 in Serum of Patients with Breast Cancer. The International Journal of Biological Markers. 14(1). 8–15. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Barac Breakdown of academic impact, for papers by Chun‐Chieh Lin Breakdown of academic impact, for papers by Camilo E. Fadul Breakdown of academic impact, for papers by Masahiko Watanabe Breakdown of academic impact, for papers by Robin Grant Breakdown of academic impact, for papers by Bhupendra Rawal Breakdown of academic impact, for papers by Summer S. Han Breakdown of academic impact, for papers by Andrew Stone Breakdown of academic impact, for papers by Andrea Pace
Rankless by CCL
2026